Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G56W1 in Postmenopausal Osteoporosis
NCT03720886Phase 2Unknown
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of teriparatide in postmenopausal osteoporosis (3 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Percentage change in bone density of the lumbar spine (L1-4) at 24 weeks. Status: unknown.
02
Drugs
teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT03720886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720886.